Application No. 10/088, 354 Amendment Dated 08/12/2 005 Reply to Office Action of 03/14/2 005

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-10. (Cancelled)

11. (Currently amended) A compound of formula (IIB)

$$R^{66}$$
 R^{66}
 R^{67}
 R^{6}
 R^{6}

or a salt, ester, amide or produg thereof where

X is O, or S, S(O) or S(O)₂, NH or NR⁸ where R⁸ is hydrogen or C₁₋₈alkyl, Z is O or S

R⁹ is hydrogen er optionally substituted hydrocarbyl or optionally substituted heterocyclyl ethenyl, optionally substituted phenyl, optionally substituted pyridyl or optionally substituted furanyl where optional substituted for R⁹ groups are C₁₋₃alkoxy, C₁₋₃alkyl, halo or nitro, R⁶ and R⁷ are independently selected from hydrogen, halo, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkoxy, C₁₋₄alkoxymethyl, di(C₁₋₄alkoxy)methyl, C₁₋₄alkanoyl, trifluoromethyl, cyano, amino, C₂₋₈alkenyl, C₂₋₈alkynyl, a phenyl group, a benzyl group or a 5-6-membered heterocyclic group with 1-3 heteroatoms, selected independently from O, S and N, which heterocyclic group may be aromatic or non-aromatic and may be saturated and [[(]]linked via a ring carbon or nitrogen atom[[[ingleta]]] or unsaturated and [[([]]linked via a ring carbon atoms up to 5 substituents selected from hydroxy, halogeno, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkanoyloxy, trifluoromethyl, cyano, amino, nitro, C₂₋₄alkanoyl, C₁₋₄alkanoylamino, C₁₋₄alkoxycarbonyl, C₁₋₄alkylsulphanyl, C₁₋₄alkylsulphinyl, C₁₋₄alkylsulphinyl, carbamoyl, N-C₁₋₄alkylcarbamoyl, N,N-di(C₁₋₄alkyl)carbamoyl,

Page 3 of 18

PAGE 7/22 * RCVD AT 8/12/2005 5:25:06 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/0 * DNIS:8729306 * CSID:17818394121 * DURATION (mm-ss):06-52

Application No. 10/088,354 Amendment Dated 08/12/2005 Reply to Office Action of 03/14/2005

aminosulphonyl, N-C₁₋₄alkylarninosulphonyl, N,N-di(C₁₋₄alkyl)aminosulphonyl, C₁₋₄alkylsulphonylamino, and a saturated heterocyclic group selected from morpholino, thiomorpholino, pyrrolidinyl, p perazinyl, piperidinyl, imidazolidinyl and pyrazolidinyl, which saturated heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkoxy, C₁₋₃alkarioyloxy, trifluoromethyl, cyano, amino, nitro and C₁₋₄alkoxycarbonyl, R¹ is hydrogen, R⁴ is hydrogen, halo, C₁₋₄alkyl or C₁₋₄alkoxy are independently selected from halogeno, cyano, nitro, C₁₋₃allylsulphanyl, N(OH)R⁴² (wherein R⁴² is hydrogen, or C₁₋₃alkyl), or R⁴⁴X⁴ (wherein X⁴ represents a direct bond, O₁ CH₂ - OC(O), C(O), S₁ SO₁ SO₂ NR⁴⁸ C(O)-, C(O)NR⁴⁸ - SO₂ NR⁴⁸ - NR⁴⁸SO₂ or NR⁴⁹ (wherein R⁴⁵, R⁴⁵, R⁴⁵, R⁴⁵ and R⁴⁹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl)), and R⁴⁴ is hydrogen, optionally substituted heterocyclyl or optionally substituted alkoxy

and n is 0, or an integer of fro n 1 to 6,

R⁶⁸ is halo, cyano, nitro, triflucromethyl, C₁₋₃alkyl, -NR¹²R¹³ [(]]wherein R¹² and R¹³, which may be the same or different, each represents hydrogen or C₁₋₃alkyl[[]], or a group -X¹R¹⁴ [[[]]wherein X¹ represents a direct bond, ¬()-, ¬CH₂-, ¬OC(O)-, ¬C(O)-, ¬S-, ¬SO-, ¬SO₂-, ¬NR¹5C(O)-, -C(O)NR¹⁶-, -SO₂NR¹⁷-, -NR¹⁸SO₂- or -NR¹⁸- [[(]]wherein R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl[[))]], and R¹⁴ is <u>hydrogen or</u> C1-salkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, oxiranyl, fluoro, chloro, bromo and amino including C1-3alkyl and trifluoromethyl; or -R⁹R³⁸ and wherein R³⁸ represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group linked via carbon or nitrogen with 1-3 heteroatoms selected from O. N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from hydroxy, nitro, halogeno, amino, C1.4alkyl, C1.4alkoxy, C1-4hydroxyalkyl, C1-4aminoalkyl, C1-4alkylamino, C1-4hydroxyalkoxy, oxo, cyanoC1-4alkyl, cyclopropyl, C1-alkylsulphonylC1-alkyl, C1-alkoxycarbonyl, di(C1-alkyl)amino, C1-alkylaminoC1-alkyl, C1-alk anoyl, di(C1-alkyl)aminoC1-alkyl, C1-alkylaminoC1-alkoxy. di(C1-4alkyl)aminoC1-4alkoxy, carboxy, carboxamido, trifluoromethyl, cyano, -C(O)NR39R40, -NR⁴¹C(O)R⁴² wherein R³⁹, R⁴¹, R⁴¹ and R⁴², which may be the same or different, each represents hydrogen, C1-alkyl, hydroxyC1-alkyl or C1-alkoxyC2-alkyl and a group -(-O-)_f(C₁₋₄alkyl)_oring D wherein f is 0 or 1, q is 0 or 1 and ring D is a cyclic group selected from C3.6 cycloalkyl, aryl or 5-6-men bered saturated or unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from halp and C1-4alkyl; and wherein R9 is a C1-8alkylene group optionally

Page 4 of 18

Application No. 10/088,354 Amendment Dated 08/12/2005 Reply to Office Action of 03/14/2005

substituted by one or more substituents selected from hydroxy, halogene and amine hydrogen, optionally substituted heterocyclyl-or optionally-substituted alkexy:

and R⁸⁷ is C₁₋₈alkoxy eptienally substituted with a group X¹R³⁸ [[(]]wherein X¹ represents a direct bend, O, CH₂, OC(O), C(O), S, SO, SO₂, NR⁴⁵C(O), C(O)NR⁴⁸, SO₂NR⁴⁷, -NR⁴⁸SO₂-or-NR⁴⁹-(wherein R⁴⁸, R⁴⁶, R⁴⁷, R⁴⁸-and R⁴⁹-each independently represents hydrogen, C₁₋₂alkyl or C₁₋₂alkyxyC₂₋₂alkyl)), and R³⁸ are as defined above is a pyridene-group, an anyl group or an aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatems selected from O, N and S, which pyridene, anyl or aromatic heterocyclic group may be substituted by one or more functional groups or by a hydrocarbyl group optionally substituted by one or more functional group; or heterocyclyl groups, or by a heterocyclyl group-optionally substituted by one or more functional groups or hydrocarbyl groups, or R⁶⁷ is 3-morpholinopropoxy; provided that R⁶⁷-is-other than unsubstituted alkoxy; or a compound of formula (IIII3)

or a salt, ester, amide or prodiug thereof,

where X, R⁴, R⁴, R⁵ and R⁷ are as defined above, and R⁶⁵ are R⁶⁷ are as defined above provided that R⁶⁷ is other than unsubstituted alkoxy; and R⁶⁷ is benzyl or cyanobenzyl or R⁵⁵ is optionally substituted phenyl, where the optional substituents include G₁₋₃ alkyl groups as well as nitro and halo or R⁵⁵ is ethynyl optionally substituted with trimethylsilyl groups, carboxy, or an C₁₋₈ alkyl ester thereof;

Ot .

a compound of formula (IVB)

Page 5 of 18

Application No. 10/088, 354 Amendment Dated 08/12/2:005 Reply to Office Action of 03/14/2:005

or a salt, ester, amide or prodrug thereof,

where X, R⁴, R⁶ and R⁷ and n are as defined above, R⁵⁵ is a group of formula NR⁴⁰ R⁴⁰ where R⁴⁰ and R⁴⁰ are independently selected from hydrogen, optionally substituted hydrocarbyl or optionally substituted heterocyclyl, or R⁴⁰ and R⁴⁰ together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring which may optionally contain further heteroatoms, or an azo group of formula N=N-R⁴⁴ where R⁴⁴ is an optionally substituted hydrocarbyl group or optionally substituted heterocyclyl group, or R⁵⁵ is a group N=NR⁴⁴ where R⁴⁴ is as defined above, and Ft⁵⁶ are R⁵⁵ are as defined above provided that R⁶⁷ is other than unsubstituted alkoxy;

Of

a-compound of formula (IVC)

or a salt, ester, amide or produg-thereof,
where R⁴, R³, R⁴ and X arr) as defined in claim 1.

Page 6 of 18

PAGE 10/22 * RCVD AT 8/12/2005 5:25:06 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/0 * DNIS:8729306 * CSID:17818394121 * DURATION (mm-ss):06-52

Application No. 10/088,854 Amendment Dated 08/12/2005 Reply to Office Action of03/14/2005

12. (Currently amended) A method of preparing a compound according to claim 11, which comprises reacting a compound of formula (VII)

where R¹′, R²′, R³′, and R⁴′ an∋ respectively equivalent to a group R¹, R⁵⁵, R⁵⁵ and R⁴ as defined in claim 11 or a precursor thereof, and R⁵⁵ is a leaving group, with a compound of formula (VIII)

where X, is as defined in claim 11, and Ra is selected from

where Z, n, R8, R7 and R9 are as defined in claim 11,

Page 7 of 18

PAGE 11/22 * RCVD AT 8/12/2005 5:25:06 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/0 * DNIS:8729306 * CSID:17818394121 * DURATION (mm-ss):06-52

Application No. 10/088,854 Amendment Dated 08/12/2005 Repty to Office Action of03/14/2005

R⁶-is an optionally substituted hydrocarbyl, optionally substituted heterosyclyl-or optionally substituted alkoxy group, provided that R⁶-is other than ethenyl substituted by a carboxy group or an amide or sulphonamide derivative thereof, and R⁵²-is halogen or a group of formula NR⁴⁰R⁴⁰-where R⁴⁰-and R⁴⁰-are independently selected from hydrogen, optionally-substituted hydrocarbyl or optionally-substituted heterosyclyl, or R⁴⁰ and R⁴⁰-together-with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring which may optionally contain further-heteroatoms, or an aze group of formula N=N-R⁴⁴-where R⁴⁴ is an optionally substituted hydrocarbyl group or optionally substituted heterocyclyl group.

13-14. (Canceled)

- 15. (Currently Amended) A pharmaceutical composition comprising a compound of formula (IIB), (IVB) or (IVC) as defined in claim 11, or a salt, ester, amide or prodrug thereof, in combination with a pharmaceutically acceptable carrier.
- 16. (Currently amended) A compound according to claim 11, selected from: a compound of formula (IIB) or a salt, ester, amide or prodrug thereof, wherein wherein X is O, S, S(O) or S(O)₂, or NR⁸ where R⁸ is hydrogen or G_{1.6}alkyl; Z is O or S,

n-is 0, or an integer from 1 to 6,

R1 and R4 are both hydrogen:

R⁹ is hydrogen, ethenyl, opticnally substituted phenyl, optionally substituted pyridyl, or optionally substituted furanyl where optional substitutents for R⁹-groups are C₄₋₃alkoxy, C₄₋₃alkyl, halo or nitro.

 \mathbb{R}^{8} -and \mathbb{R}^{3} -are independently-selected from hydrogen, halo, \mathbb{C}_{4} -alkyl, $\mathbb{C}_{4,4}$ -alkexy, $\mathbb{C}_{4,4}$ -alkexy, $\mathbb{C}_{4,4}$ -alkexy, $\mathbb{C}_{4,4}$ -alkexy, $\mathbb{C}_{4,4}$ -alkexy, $\mathbb{C}_{2,4}$ -alkexy, $\mathbb{C}_{2,4}$ -alkexy, $\mathbb{C}_{2,4}$ -alkexy, $\mathbb{C}_{2,4}$ -alkexy, $\mathbb{C}_{2,4}$ -alkexy, $\mathbb{C}_{2,4}$ -alkynyl, a phenyl-group, a benzyl-group or a 5-6 membered heterocyclic group with 1–3 heteroatems, selected independently from $\mathbb{Q}_{4,4}$ -and $\mathbb{Q}_{4,4}$ -alkexy aring carbon or nitrogen atom) or are matic or non-aromatic and may be saturated (linked via a ring carbon or nitrogen atom) or uncaturated (linked via a ring carbon atom), and which phenyl, benzyl or heterocyclic group may bear on one or more ring carbon atoms up to 5 substituents selected from hydroxy, halogeno, $\mathbb{C}_{4,4}$ -alkoxy, $\mathbb{C}_{4,3}$ -alkanoylexy, trifluoromethyl, cyano, amino, nitro, $\mathbb{C}_{2,4}$ -alkyleulphonyl, $\mathbb{C}_{4,4}$ -alkyleulphonyl, \mathbb{C}

Page 8 of 18

PAGE 12/22 * RCVD AT 8/12/2005 5:25:06 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/0 * DNIS:8729306 * CSID:17818394121 * DURATION (mm-ss):06-52

Application No. 10/088,854 Amendment Dated 08/12/2005 Reply to Office Action of 03/14/2005

carbamoyl, N-C, alkylcarbanioyl, N,N-di(C, alkyl)carbamoyl, aminoculphonyl, N-C_{1-a}alkylaminosulphonyl, N,N-di(C_{1-a}alkyl)aminosulphonyl, C_{1-a}alkylsulphonylamino, and-a saturated heterocyclic group selected from morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl, imidazelidinyl-and pyrazelidinyl, which saturated heterocyclic group may bear 1 or 2 substituents selected from exe, hydroxy, halogene, C₁₋₃alkyl, C₁₋₃alkoxy, G₁₋₃alkanoyloxy, trifluoromethyl. cyano, amino nitro and C. alkoxycarbonyl, R⁵⁶ is halo, cyano, nitro, triflu-romethyl, C₁₋₃alkyl, NR¹³R¹³ (wherein R¹² and R¹³, which may be the same or different, each represent hydrogen or C1 alkyl), or a group X1R14 where X1 represents a direct band, -O-, -CH2-, -OC(O)-, -C(O)-, -S-, -SO-, -SO2-, -NR45C(O)-, -C(O)NR46-, -SO₂NR¹⁷, NR¹⁰SO₂ or NR¹⁸ (wherein R¹⁵, R¹⁵, R¹⁵, R¹⁸ and R¹⁰ each independently represent hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R¹⁴ is a group (1) where group (1) is hydrogen or C_{1-s}alkyl which niay be unsubstituted or which may be substituted with one or more groups selected from hydrox), exiranyl, fluoro, chloro, brome and amine (including C1.alkyl and trifluoromethyl); or a group (10) where group (10) is ReRad wherein Rad represents a pyridone group, a phonyl group or a 5-6-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms-selected from O. N and S, which pyridene, phenyl or aromatic heterocyclic group may carry up to 5 substituents-selected from hydroxy, nitro, halogeno, amino, C., alkyl, C. alkoxy, C., hydroxyalkyl, C., aminoalkyl, C., alkylamino, C4.4hydroxyalkoxy, oxo, cyan; C4.4alkyl, cyclopropyl, C4.4alkylsulphonylC4.4alkyl, C__alkoxycarbonyl, di(C__alk_/l)amino, C__alkylaminoC__alkyl, C__alkanoyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy, carboxy, carboxamido, trifluoromethyl, cyano, -C(O)NR³⁶R⁴⁶, -NR⁴¹C(O)R⁴² (wherein R³⁶, R⁴⁶, R⁴¹ and R⁴², which may be the same or different, each represents hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl or C1. alkoxyC2.alkyl) and a stroup -(-O-),(C1.4alkyl), ringD (whorein f is 0 or 1, g-is 0 or 1 and ring D is a cyclic-group selected fram C₃₋₆cycloalkyl, aryl or 5-6-membered-saturated-or-unsaturated heterocyclic group with 1-2 heteroatems, selected independently from O, S and N, which cyclic group-may-bear-one-or-more-substituents selected from halo and C14alkyl); and wherein Rº is a C_{1.8}alkylene-group-optionally-substituted-by-one or more substituents selected from hydroxy, halogeno and amino, and Rex is 3-morpholinoproperty: OF a-compound of formula (IIIB) or a calt, ester, amide or prodrug thereof.

Page 9 of 18

wherein X, R1, R4, R6, R7 and R66 are as defined above

Application No. 10/088,854 Amendment Dated 08/12/2005 Reply to Office Action of03/14/2005

R⁶⁷ is C₁₋₆alkexy-optionally substituted with fluorine or a group X⁴R³⁸ in which X⁴ represents a direct bond, O₁ CH₂ OCC) carbonyl, S₁ SO₂ SO₂ NR⁴²CO₂ CONR⁴² - SO₂NR⁴² - NR⁴³SO₂ or NR⁴⁴ (whereir R⁴², R⁴³ and R⁴⁴ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R³⁸ represents a pyridone group, a phenyl group or a 5-6 membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatems selected from O₁ N and S₁ which pyridone, phenyl or aromatic heterocyclic group may carry up to 5-cubstituents on an available carbon atom selected from hydroxy, halogene, amine, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄hydroxyalkyl, C₁₋₄aminealkyl, C₁₋₄alkylamine, C₁₋₄hydroxyalkoxy, carboxy, trifluoremethyl, cyane, CONI3³⁰R⁴⁰ and NR⁴¹COR⁴² (wherein R³⁸, R⁴⁰, R⁴¹ and R⁴², which may be the same or different, cach represents hydrogen, C₁₋₄alkyl or C₁₋₃alkoxyC₂₋₃alkyl); wherein at least R⁶⁷ is other than unsubstituted alkoxy; and R⁶ is optionally substituted phenyl, where the optional

and R^c-ic-benzyl and cyanobenzyl or R^c is optionally substituted phenyl, where the optional substituents include C₁₋₃ alky groups as well as nitro and halo or R^c is othynyl optionally substituted with trimethylsilyl groups, carboxy, or an C_{1-s}alkyl ester thereof

a compound of formula (IVB) or a salt, ester, amide or prodrug thereof, where X, R⁴, R⁶ and R⁷ are as defined in relation to formula (IIB) above

R^{5°}-a group of formula NR¹⁰R^{10°}-where R⁴⁰-and R^{40°}-are independently-selected from hydrogen, alkyl or heterocyclyl, or R⁴⁰-and R^{40°}-together with the nitrogen atom to which they are attached form a morpholino or terahydropyridyl or R^{5°} is a group N=NR⁴⁴-where R⁴⁴ is alkyl or phenyl or heterocyclyl

and Rea are Re7-are as defined in relation to formula (IIIB) above;

a compound of formula (IVC) or a salt, ester, amide or prodrug thereof,

where X, R⁴, R⁴ are as defined in relation to formula (IIB) above

R²-and R³-are independently selected from, halo, syano, nitro, trifluoromethyl,

C₁₋₃alkyl, NR⁹R⁴⁰ (wherein-R⁹-and-R⁴⁰, which may be the same or different, each represents hydrogen or C₁₋₃alkyl), or -X¹-R¹⁴ (wherein X¹ represents a direct-bond, O-, -CH₂-, -OCO ,

carbenyl, S., SO., SO₂., AR¹²CO., CONR¹²., SO₂NR¹²., NR¹³SO₂ or NR¹⁴- (wherein R¹², R¹⁴-and R¹⁴-each independently represents hydrogen, C₁₋₂alkyl or C₁₋₂alkexyC₂₋₂alkyl), and R¹⁴-is

selected from one of the following-groups:

1') hydrogen or G_{1 salkyl} which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluore-or-amine,

Page 10 of 18

PAGE 14/22 * RCVD AT 8/12/2005 5:25:06 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/0 * DNIS:8729306 * CSID:17818394121 * DURATION (mm-ss):06-52

```
Application No. 10/088,854
Amendment Dated 08/12/2005
Reply to Office Action of03/14/2005
```

2') C₁₋₆alkylX²COR²⁰ (whereir: X²-represents -O- or -NR²⁴- (in which R²⁹-represents hydrogen, C₁₋₃alkyl-or C₁₋₃alkoxyC₂₋₃alkyl) and R²⁴-represents C₁₋₃alkyl, -NR²²R²³-or-OR²⁴ (wherein R²², R²³ and R24 which may be the same or different each represents hydrogen, C43alkyl or C1-3alkoxyC2-3alkyl); 3') C1. alkylX3R25 (wherein X3 represents O + S + SO + SO2 + OCO + NR35CO + CONR27 + -SO₂NR²⁸-, -NR²⁰SO₂- or -NR³⁰- (wherein R²⁶-, R²⁷-, R²⁸, R²⁹- and R³⁰-each independently represents hydrogen, C1-2alkyl or C1-3alkoxyC2-3alkyl) and R26 represents hydrogen, C1-3alkyl, cyclopentyl, cyclohexyl or a 5-6-membered saturated heterocyclic group with 1-2-heteroatoms, selected independently from 13, S and N, which C_{1-x}alkyl group may bear 1 or 2 substituents selected from exe, hydroxy, halogene and C₄₋₄alkexy and which cyclic group may bear 1 or 2 substituents-selected-from-exe, hydroxy, halogene, C+4alkyl, C+4hydroxyalkyl and C+4alkexy); 4")-C_{1-r}alkvIX⁴C_{1-r}alkvIX⁵R²¹-(vherein X⁴-and X⁵-which may be the same or different are each -O--S--SO--SO₂--NR³²C-J--CONR³³--SO₃NR³⁴--NR³⁶SO₂-or-NR³⁶-(wherein-R³²-R³³-R³⁴, R³⁵ and R³⁶ each independently represents hydrogen, C_{1,3}alkyl or C_{1,3}alkexyC_{2,3}alkyl) and R34 represents hydrogen or C+ aalkyl); 5') R32 (wherein R32 is a 5-6-n)embered saturated heterocyclic group (linked via carbon or nitregen) with 1.2 heteroatoms, selected independently from 0, S and N, which heterocyclic eroup may bear 1 or 2 substituents selected from exe, hydroxy, halogene, G₁₋₄alkyl, G_{1.4}hydroxyalkyl, G_{1.4}alkoxy, G_{1.4}alkoxyG_{1.4}alkyl and G_{1.4}alkylsulphenylG_{1.4}alkyl); 6')-C₁₋₅alkylR³⁷-(wherein-R³⁷-it:-ac-defined-hereinbefere in (5')); 7') C2 salkenylR37 (wherein R37 is as defined hereinbefore in (5')); 8') C2 salkynylR37 (wherein R3' is as defined hereinbefore in (5')); 9') R38 (wherein R38 represents a pyridone group, a pheny) group or a 5-6-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, N-and S, which pyridene, phenyl or arematic heterocyclic group-may carry up to 5 substituents on an available-carbon atom-selected from hydroxy, halogene, amine, C14alkyl, C44alkoxy, C14hydroxyalkyl, C14aminoall:yl, C14alkylamino, C14hydroxyalkoxy, carboxy, trifluoromethyl, cyano, CONR30R40 and NR41 COR42 (wherein R30, R40, R41 and R42, which may be the same or different-each-represents hydrogen, C+4alkyl or C+3alkexyC2-3alkyl)); 40") CapalkyIR38 (wherein R38 - s as defined hereinbefore in (9')); 11') C2 salkenyIR38 (wherein R38 is as defined hereinbefore in (9'));

Page 11 of 18

12') C2-salkynyIR38 (wherein R38 is as defined hereinbefore in (8'));

Application No. 10/088,854 Amendment Dated 08/12/2005 Reply to Office Action of 03/14/2005

13') C₁₋₆alkylX⁶R⁴⁸ (wherein): represents O, S, SO, SO₂, NR⁴³CO, CONR⁴⁴, SO₂NR⁴⁵, NR⁴⁶SO₂ or NE, T, (wherein R⁴³, R⁴⁴, R⁴⁵, R⁴⁶ and R⁴⁷ each independently represents hydrogen, C₁₋₂alkyl or C₁₋₂alkoxyC₂₋₃alkyl) and R²⁸ is as defined hereinbefore in (8')); 14') C₂₋₆alkenylX⁷R³⁸ (whereh X, represents O, S, SO, SO₃, NR⁴⁸CO, CONR⁴⁰, SO₂NR⁶⁰, NR⁶⁴SO₂ or NE, S, (wherein R⁴⁸, R⁴⁸, R⁶⁰, R⁶⁴ and R⁶² each independently represents hydrogen, C₁₋₂alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R³⁸ is as defined hereinbefore in (8')); 15') C₂₋₆alkynylX⁸R³⁸ (wherein X, represents O, S, SO, SO₂, NR⁶³CO, CONR⁶⁴, SO₃NR⁶⁵, NR⁶⁶SO₃ or NE, S, (wherein R⁶³, R⁶⁴, R⁶⁶, R⁶⁶ and R⁶⁷ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R³⁸ is as defined hereinbefore in (8')); 16') C₁₋₃alkylX⁶C₁₋₃alkylR³⁶ (wherein X, represents O, S, SO, SO₃, NR⁶⁶CO, CONR⁶⁸, SO₂NR⁶⁹, NR⁸⁴SO₂ or NE, S, (wherein R⁶⁸, R⁶⁸, R⁶⁹, R⁶⁴, and R⁶² each independently represents hydrogen, C₁₋₃alkylR³⁶ (wherein R⁶⁸, R⁶⁸, R⁶⁹, R⁶⁴, and R⁶² each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R³⁸ is as defined hereinbefore in (8')); and

- 17. (new) A compound according to claim 11 wherein R⁶⁷ is 3-morpholinopropoxy.
- 18. (new) A compound according to claim 11 wherein R⁸ and R⁷ are independently selected from hydrogen, halo, C₁₋₄alk(xy, cyano, trifluoromethyl or phenyl.
- 19. (new) A compound according to claim 11 wherein R⁶ and R⁷ are both hydrogen.
- 20. (new) A compound according to claim 11 wherein the prodrug is a phosphate or sulphate or an alkyl, aryl or aralkyl derivative thereof.
- 21. (new) A method of treating colorectal or breast cancer in a warm blooded animal comprising administering to said animal an effective amount of a compound according to claim 11 or a salt or prodrug thereof.